The Japan presidents of foreign pharma companies are no longer hiding their concerns about the stagnation of drug development in the Japanese market. In their business briefings for 2021, many of them made explicit criticism against what they see as…
HOME > ACADEMIA
ACADEMIA
- Treatment with Corticosteroids Strongly Recommended for Sclerosing Cholangitis: New Guidelines
May 9, 2019
- Risk of Relapse Will Be Challenge for CAR-T Cell Therapy: Immunologist
May 8, 2019
- Niigata Univ., Eisai Team Up to Develop Pancreatic Cancer Drug Using Highly Absorbed Peptide
May 7, 2019
- Revised Hypertension Treatment Guidelines Set Stricter Blood Pressure Reduction Target
April 23, 2019
- Xofluza Shouldn’t Be Used Alone for Hong Kong Flu: Specialist
April 8, 2019
- With Continuing Shortage of Cefazolin, Shipments of 21 Substitutes Being Adjusted Too
April 8, 2019
- Discuss Biosimilar Pricing Separate from High-Cost Medical Expense Benefits: Prof.
March 20, 2019
- NCNP to Set Up New Council to Accelerate Clinical Development of Neuromuscular Disorder Treatments
March 18, 2019
- Feburic Prevents Cerebral, Cardiorenovascular Events: Japan Multicenter Study
March 13, 2019
- Investigators Calling Off Trials on First Hyperlactacidemia Drug with No Significant Improvement Shown
February 28, 2019
- Keio Researchers Start Studying ReQuip for ALS after iPS Screening
February 25, 2019
- Revised Hyperuricemia Treatment Guidelines Recommend Uric Acid Production Inhibitors to Prevent Kidney Function Decline
January 21, 2019
- Concomitant Insulin a Must for Suglat Use in Type 1 Diabetes: Specialist
January 18, 2019
- 8-Week Treatment with Maviret a Promising First-Line Option for Hepatitis C: Hepatologist
January 11, 2019
- Tokyo Medical and Dental Univ. to Launch Investigator-Led Trial for JAK Inhibitor for CAEBV
January 10, 2019
- Health Economist Calls for Robust Appraisal Process in Japan CEA System
November 20, 2018
- Hematology Specialist Advises Caution in Using Hemlibra in Children
October 30, 2018
- Research Group Builds New Pathogenic Variants Database for Japanese Hereditary Breast Cancer
October 16, 2018
- I/O Pioneers Win Nobel Prize in Medicine; Honjo Prods Japan Firms to Make More Academic Investment at Home
October 2, 2018
- New Treatment GL for Statin Intolerance Compiled by Atherosclerosis Society, 3 Other Academic Societies
October 1, 2018
ページ
The missing ingredient for managers is not their skill, ability, or education. Academic achievements and business success will get runs on the board, to a certain level. However, that is just half of the story.Leaders come in all shapes and…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…